Kirk D Beebe
Overview
Explore the profile of Kirk D Beebe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eisner J, de Jong F, Shibata Y, Mayhew G, Davison J, Carcione J, et al.
Clin Cancer Res
. 2024 Sep;
30(23):5374-5384.
PMID: 39325014
Purpose: The Genomic Analysis of High-Risk Non-Muscle-Invasive Bladder Cancer (GARNER) study investigated FGFR alteration (ALT) frequency and the clinical outcome relationship with Bacillus Calmette-Guérin (BCG) treatment in high-risk non-muscle-invasive bladder...
2.
Beebe K, Eisner J, Guo J, Shibata Y, Davison J, Uronis J, et al.
J Immunol
. 2024 May;
213(1):29-39.
PMID: 38767437
High-dose (HD) IL-2 was the first immuno-oncology agent approved for treating advanced renal cell carcinoma and metastatic melanoma, but its use was limited because of substantial toxicities. Multiple next-generation IL-2...
3.
Eisner J, Mayhew G, Davison J, Beebe K, Shibata Y, Guo Y, et al.
Clin Cancer Res
. 2023 May;
29(16):3203-3213.
PMID: 37233991
Purpose: The Piedmont study is a prospectively designed retrospective evaluation of a new 48-gene antifolate response signature (AF-PRS) in patients with locally advanced/metastatic nonsquamous (NS) non-small cell lung cancer (NSCLC)...
4.
Eisner J, Beebe K, Mayhew G, Shibata Y, Guo Y, Farhangfar C, et al.
Cancer Res Commun
. 2023 Mar;
2(8):894-903.
PMID: 36923304
Significance: Next-generation IL2 agents, designed for improved tolerability over traditional HD-IL2 (aldesleukin), are in clinical development. Retrospective molecular tumor profiling of patients treated with HD-IL2 or anti-PD-1 therapy provides insights...
5.
Spitale R, Cheng M, Chun K, Gorell E, Munoz C, Kern D, et al.
Genome Med
. 2012 Feb;
4(2):14.
PMID: 22360970
Background: Cigarette smoking is well-known to associate with accelerated skin aging as well as cardiovascular disease and lung cancer, in large part due to oxidative stress. Because metabolites are downstream...
6.
Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn M, et al.
Toxicol Pathol
. 2009 May;
37(4):521-35.
PMID: 19458390
Peroxisome proliferator-activated receptor-alpha (PPARalpha) agonists such as fenofibrate are used to treat dyslipidemia. Although fenofibrate is considered safe in humans, it is known to cause hepatocarcinogenesis in rodents. To evaluate...
7.
Arabaci G, Yi T, Fu H, Porter M, Beebe K, Pei D
Bioorg Med Chem Lett
. 2002 Oct;
12(21):3047-50.
PMID: 12372498
A series of alpha-haloacetophenone derivatives was tested for inhibition of protein tyrosine phosphatases SHP-1 and PTP1B. The results show that the bromides are much more potent than the corresponding chlorides,...